Keyphrases
Meta-analysis
100%
Acute Myeloid Leukemia
100%
Systematic Meta-analysis
100%
Maintenance Therapy
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Overall Survival
60%
Tyrosine Kinase Inhibitor
40%
Hypomethylating Agents
40%
Relapse-free Survival
40%
Graft-versus-host Disease (GvHD)
40%
Post-transplant Management
40%
In(III)
20%
Placebo
20%
Randomized Controlled Trial
20%
Leukemia Patients
20%
Adverse Events
20%
Subgroup Analysis
20%
Meta-analysis of Randomized Controlled Trials
20%
PubMed
20%
Safety Profile
20%
Sorafenib
20%
Patient Death
20%
Leukemia Disease
20%
Cochrane Library
20%
Inhibitor Agent
20%
Relapse Risk
20%
Disease Relapse
20%
Transplant Failure
20%
Control Arm
20%
Conference Proceedings
20%
Transplant Patients
20%
Decitabine
20%
Midostaurin
20%
Azacytidine
20%
Medicine and Dentistry
Meta-Analysis
100%
Acute Myeloid Leukemia
100%
Systematic Review
100%
Maintenance Therapy
100%
Arm
60%
Overall Survival
60%
Infection
40%
Randomized Controlled Trial
40%
Tyrosine-Kinase Inhibitor
40%
Recurrence Free Survival
40%
Hematopoietic Stem Cell Transplantation
40%
Hypomethylating Agent
40%
Placebo
20%
Adverse Event
20%
Subgroup Analysis
20%
Azacitidine
20%
Acute Graft Versus Host Disease
20%
Chronic Graft Versus Host Disease
20%
Decitabine
20%
Sorafenib
20%
Midostaurin
20%
Diseases
20%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
100%
Overall Survival
75%
Infection
50%
Randomized Controlled Trial
50%
Recurrence Free Survival
50%
Protein Tyrosine Kinase Inhibitor
50%
Placebo
25%
Adverse Event
25%
Sorafenib
25%
Azacitidine
25%
Decitabine
25%
Acute Graft Versus Host Disease
25%
Chronic Graft Versus Host Disease
25%
Midostaurin
25%
Diseases
25%